Open AccessMeasuring cognition and function in the preclinical stage of Alzheimer's disease
Author(s) -
Weintraub Sandra,
Carrillo Maria C.,
Farias Sarah Tomaszewski,
Goldberg Terry E.,
Hendrix James A.,
Jaeger Judith,
Knopman David S.,
Langbaum Jessica B.,
Park Denise C.,
Ropacki Michael T.,
Sikkes Sietske A.M.,
WelshBohmer Kathleen A.,
Bain Lisa J.,
Brashear Robert,
Budur Kumar,
Graf Ana,
Martenyi Ferenc,
Storck Marta Segardahl,
Randolph Christopher
Publication year - 2018
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1016/j.trci.2018.01.003
Subject(s) - disease , cognition , alzheimer's disease , clinical trial , medicine , psychology , neuroscience , pathology
The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.